TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma-Reference-Cited by-同舟云学术

TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma

Published:2009-09-04 Issue:11 Volume:22 Page:1415-1422
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Albadine Roula,Latour Mathieu,Toubaji Antoun,Haffner Michael,Isaacs William B,A Platz Elizabeth,Meeker Alan K,Demarzo Angelo M,Epstein Jonathan I,Netto George J

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/modpathol2009121.pdf

Reference28 articles.

1. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644–648.

2. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538–544.

3. Wang J, Cai Y, Yu W, et al. Pleiotropic biological activities of alternatively spliced TMPRSS2–ERG fusion gene transcripts. Cancer Res 2008;68:8516–8524.

4. Cerveira N, Ribeiro FR, Peixoto A, et al. TMPRSS2–ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 2006;8:826–832.

5. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2–ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882–888.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Pathology of Prostate Cancer;Clinics in Laboratory Medicine;2024-06

2. What is cancer? A focus on Grade Group 1 prostate cancer;BJU International;2024-01-16

3. Prognostic Values of Gene Copy Number Alterations in Prostate Cancer;Genes;2023-04-22

4. Clonal relationships of adjacent Gleason pattern 3 and Gleason pattern 5 lesions in Gleason Scores 3+5=8 and 5+3=8;Human Pathology;2022-12

5. Characterization of stage‐specific tumor progression in TMPRSS2‐ERG (fusion)‐driven and non‐fusion‐driven prostate cancer in GEM models;Molecular Carcinogenesis;2022-04-22